GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
GEn1E Lifesciences is a clinical-stage, Phase 2 company focused on accelerating 1st-in-class precision therapies for inflammatory and rare diseases with unprecedented efficiency. Leveraging seed capital, GEn1E has rapidly advanced from early discovery to Phase 2 in just 2.5 years.
GEn1E Lifesciences operates on a scalable drug development model, unlocking a $100 billion+ opportunity by combining team expertise, advanced technology, and targeted therapies.
GEn1E's team comprises experts in drug discovery, clinical trials, and machine learning. The company’s unique approach integrates a rich database of curated data and machine learning models to accelerate the drug development cycle, ensuring efficient and effective treatment solutions for patients with rare and inflammatory diseases.
Unleashing the potential of DNA and RNA based therapies using AI
Make undruggable targets a thing of the past
AI for Pharma Intelligence
We use AI to design antibodies for intractable diseases
Combinations therapy by rational design
AI for enhanced functional proteins
Nomic is doing for proteins what Illumina has done for DNA
The better way to run single cell genomics
Multi-targeted therapeutics to treat complex diseases
The robotic cloud laboratory for the life sciences.
Match with like-minded professionals for 1:1 conversations
Go from Slack Chaos to Clarity in Minutes
Personalize 1000s of landing pages in under 30 mins
The first LLM for document parsing with accuracy and speed
AI Assistants for SaaS professionals
AI-powered phone call app with live translation
Delightful AI-powered interactive demos—now loginless
AI Motion Graphics Copilot
Pop confetti to get rid of stress & anxiety, 100% AI-free
Smooth payments for SaaS